Press Release: Wegovy (Semaglutide) now approved for MASH

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/66/77/29/667729bb-b72a-4abb-8a66-d0f293806148/mza_16977989797155034764.jpg/600x600bb.jpg

Skinfluenced - The Skin Podcast

15 episodes

6 days ago

🧴 Harnessing the power of technology, Skinfluenced: The Skin Podcast keeps you plugged into the fast-moving worlds of dermatology, wellness, and aesthetics. From the latest journal articles and groundbreaking studies, to new FDA approvals, new product launches, and clinical insights—this podcast is your go-to source for evidence-based updates that matter. Whether you're a seasoned provider or just dipping your toe in the sand, you'll stay one step ahead of the trends, the science, and your skin. Disclaimer: All content is for educational purposes only and does not constitute medical advice.

Medicine

Health & Fitness

RSS

All content for Skinfluenced - The Skin Podcast is the property of Skinfluenced - The Skin Podcast and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/44144955/44144955-1756517939215-bb16677cbc4a4.jpg

Press Release: Wegovy (Semaglutide) now approved for MASH

Skinfluenced - The Skin Podcast

12 minutes 27 seconds

2 months ago

Press Release: Wegovy (Semaglutide) now approved for MASH

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we take a break from only skin diseases, and delve into our wellness side to take a look into some ground breaking research shaping the understanding and treatment of the newest GLP-1 indication: metabolic dysfunction–associated steatohepatitis (MASH). Join us as we dive into the groundbreaking developments surrounding semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and its expanding therapeutic potential from upcoming FDA approvals to emerging pharmacologic strategies, this episode breaks down what these findings mean for providers, patients, and the future of disease management.
#Semaglutide #MASH #LiverDisease #GLP1agonist #Wegovy #LiverFibrosis #Steatohepatitis #MetabolicHealth #Obesity #Type2Diabetes #WeightLoss #Cardiometabolic #ClinicalTrials #FDAApproval #ESSENCEtrial #HeartFailure #HFpEF #ChronicKidneyDisease #NeurodegenerativeDiseases #AlzheimersDisease #ParkinsonsDisease #MASLD #NAFLD #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast

Link to Source(s):

FDA (2024): FDA Approves Treatment for Serious Liver Disease Known as MASH
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash

Journal of Hepatology (2020): A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement
https://www.sciencedirect.com/science/article/abs/pii/S0168827820302014

PubMed (2022): Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases: A Narrative Review
https://pubmed.ncbi.nlm.nih.gov/35650449/

PubMed (2023): Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Disease
https://pubmed.ncbi.nlm.nih.gov/37899788/

PubMed (2024): Semaglutide Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trials
https://pubmed.ncbi.nlm.nih.gov/39222642/

PubMed (2025): Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis
https://pubmed.ncbi.nlm.nih.gov/40004240/

The New England Journal of Medicine (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
https://www.nejm.org/doi/full/10.1056/NEJMoa2307563

The New England Journal of Medicine (2025): Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
https://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf